Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.

doi:10.1056/NEJMoa2303810

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.

The New England journal of medicine - 24 Aug 2023

Sacher Adrian, LoRusso Patricia, Patel Manish R, Miller Wilson H, Garralda Elena, Forster Martin D, Santoro Armando, Falcon Alejandro, Kim Tae Won, Paz-Ares Luis, Bowyer Samantha, de Miguel Maria, Han Sae-Won, Krebs Matthew G, Lee Jong-Seok, Cheng Michael L, Arbour Kathryn, Massarelli Erminia, Choi Yoonha, Shi Zhen, Mandlekar Sandhya, Lin Mark T, Royer-Joo Stephanie, Chang Julie, Dharia Neekesh V, Schutzman Jennifer L, Desai Jayesh

Abstract excerpt

BACKGROUND: Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity. METHODS: In a phase 1 study, we evaluated divarasib administered orally once daily (at doses ranging from 50 to 400 mg) in patients who had advanced or metastatic solid tumors that harbor a KRAS G12C mutation. The primary objective was an assessment of safety; pharmacokinetics,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Carcinoma, Non-Small-Cell Lung

Share to Colorectal Neoplasms

Share to Enzyme Inhibitors

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed

Identifiers

PMID: 37611121
DOI: 10.1056/NEJMoa2303810

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.PMID 37611121Read ↗

Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C.Semantic proximity Read ↗

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.Semantic proximity Read ↗

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.Semantic proximity Read ↗

Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.Semantic proximity Read ↗

Clinical Outcomes and Safety Profile of Adagrasib in KRAS G12C-Mutated Solid Tumors: A Single-Arm Meta-Analysis.Semantic proximity Read ↗

Adagrasib: First Approval.Semantic proximity Read ↗

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.Semantic proximity Read ↗

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.Semantic proximity Read ↗

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Semantic proximity Read ↗

[Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions].Semantic proximity Read ↗

Efficacy and toxicity of KRASG12C inhibitors in advanced solid tumors: a meta-analysis.Semantic proximity Read ↗

An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.